Filter posts

Shoppers Already Have a Choice Regarding Biotech Foods

Food Chemical News (an Agra Informa publication) ran a thorough editorial in its February 17 …

Oncology Clinical Trials - Secrets of Success

At last year’s BIO CEO & Investor Conference, BIO and BioMedTracker presented data showing that …

Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation

The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel …

Picks and Pans – The Buy-Side View for 2012

What’s the forecast for biotech in 2012? Do investors think it is a good time …

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO …

Managing in a Cost-Constrained Environment

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at …

Governor Chris Christie Will Headline BioNJ 2012 Annual Meeting

BioNJ, the trade association for New Jersey’s biotechnology industry, will welcome New Jersey Governor Chris …

Where's the Deal?

With only two weeks to go in 2011 it is looking like a five year …

Reverse Mergers: A Company is Ready to Go Public, or it’s Not

The latest IPO window has stalled. There have been five IPO withdrawals since June and …

Perspective on Market Valuation for Biotech Drug Developers

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% …